From anemia to polycythemia in 4 weeks

Primary polycythemia (PCV) may coexist in otherwise asymptomatic patients particularly in the presence of unsuspecting conditions such as Thrombotic thrombocytopenic purpura (TTP). In presumed “idiopathic TTP,” autoimmune conditions such as rheumatoid arthritis (RA) should be investigated as a possi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, Omer A., Moey, Melissa Y. Y., Papageorgiou, Christos N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582235/
https://www.ncbi.nlm.nih.gov/pubmed/28878919
http://dx.doi.org/10.1002/ccr3.879
_version_ 1783261147587149824
author Hassan, Omer A.
Moey, Melissa Y. Y.
Papageorgiou, Christos N.
author_facet Hassan, Omer A.
Moey, Melissa Y. Y.
Papageorgiou, Christos N.
author_sort Hassan, Omer A.
collection PubMed
description Primary polycythemia (PCV) may coexist in otherwise asymptomatic patients particularly in the presence of unsuspecting conditions such as Thrombotic thrombocytopenic purpura (TTP). In presumed “idiopathic TTP,” autoimmune conditions such as rheumatoid arthritis (RA) should be investigated as a possible etiology for TTP. Standardization of targeted therapy with immunomodulatory agents may be recommended for this subset of patients.
format Online
Article
Text
id pubmed-5582235
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-55822352017-09-06 From anemia to polycythemia in 4 weeks Hassan, Omer A. Moey, Melissa Y. Y. Papageorgiou, Christos N. Clin Case Rep Case Reports Primary polycythemia (PCV) may coexist in otherwise asymptomatic patients particularly in the presence of unsuspecting conditions such as Thrombotic thrombocytopenic purpura (TTP). In presumed “idiopathic TTP,” autoimmune conditions such as rheumatoid arthritis (RA) should be investigated as a possible etiology for TTP. Standardization of targeted therapy with immunomodulatory agents may be recommended for this subset of patients. John Wiley and Sons Inc. 2017-08-03 /pmc/articles/PMC5582235/ /pubmed/28878919 http://dx.doi.org/10.1002/ccr3.879 Text en © 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Hassan, Omer A.
Moey, Melissa Y. Y.
Papageorgiou, Christos N.
From anemia to polycythemia in 4 weeks
title From anemia to polycythemia in 4 weeks
title_full From anemia to polycythemia in 4 weeks
title_fullStr From anemia to polycythemia in 4 weeks
title_full_unstemmed From anemia to polycythemia in 4 weeks
title_short From anemia to polycythemia in 4 weeks
title_sort from anemia to polycythemia in 4 weeks
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582235/
https://www.ncbi.nlm.nih.gov/pubmed/28878919
http://dx.doi.org/10.1002/ccr3.879
work_keys_str_mv AT hassanomera fromanemiatopolycythemiain4weeks
AT moeymelissayy fromanemiatopolycythemiain4weeks
AT papageorgiouchristosn fromanemiatopolycythemiain4weeks

Ejemplares similares